Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 133
Filter
4.
Eur J Med Genet ; 65(11): 104609, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36096471

ABSTRACT

BACKGROUND: Gastrointestinal stromal tumors have been detected in 25% of the necropsies performed on NF1 patients, but have been reported only in 7% of NF1 patients in the largest series. Such data imply an important gap between the true presence of tumors and those diagnosed. Few genotype-phenotype relationships have been described but to date none referring to abdominal tumors. OBJECTIVES: Evaluate retrospectively the efficacy of a regular and proactive follow-up of NF1 patients to early diagnose abdominal tumors and report their mutations. METHODS: Cohort study performed between 2010 and 2020, with 43 NF1 adult patients followed at our Dermatology department. RESULTS: Eight abdominal tumors were diagnosed in six patients, meaning that 14% of the followed patients developed an abdominal tumor. Five patients (83%) were asymptomatic. Five (83.3%) had a family history of NF1 with abdominal tumors (patients 1,2 and 3,4,5 were relatives). CONCLUSIONS: Although currently gastrointestinal routine screening investigations for asymptomatic patients are not recommended in the guidelines, the family aggregation in our series suggests it should be considered a close follow-up of the relatives of a patient with an NF1-related abdominal tumor. Also, for the first time, two mutations [c.2041C > T (p.Arg681Ter) and c.4537C > T (p.Arg1513*)] have been associated with family aggregation of abdominal tumors in NF1 patients.


Subject(s)
Abdominal Neoplasms , Neurofibromatosis 1 , Abdominal Neoplasms/complications , Abdominal Neoplasms/genetics , Cohort Studies , Genotype , Humans , Neurofibromatosis 1/complications , Neurofibromatosis 1/genetics , Neurofibromatosis 1/pathology , Phenotype , Retrospective Studies
5.
Clin Transl Oncol ; 22(8): 1407-1413, 2020 Aug.
Article in English | MEDLINE | ID: mdl-31927720

ABSTRACT

BACKGROUND: Given the lack of evidence on the best adjuvant approach, this review closely examines optimal adjuvant management for resected true ampullary cancer and its histological subtypes. MATERIALS AND METHODS: A comprehensive literature search of PubMed was performed to identify studies on resected true ampullary cancers, published between January 2010 and December 2018. Data including the use of radiation, chemotherapy or chemoradiation and the outcomes were extracted. RESULTS: A total of 116 records were identified, of which 65 screened were selected. Finally, nine studies were included. Only two of the studies reported separately the outcomes of pancreatobiliary and intestinal subtypes. Patients in the selected studies were treated with a pancreaticoduodenectomy with negative margins. Patients treated with adjuvant therapy were more likely to be pT3-4 and have positive nodes; median survival ranged from 30 to 47 months. A significant benefit for adjuvant treatment was observed in four of the studies, restricted to patients at stage IIB or higher. Likewise, patients with positive nodes may have a longer median survival with adjuvant chemoradiation compared to observation. CONCLUSIONS: The present review suggests a benefit for adjuvant treatment for patients with locally advanced tumors. Randomized trials are needed to ascertain the topic, as well as studies reporting toxicity and quality of life of resected true ampullary cancer patients.


Subject(s)
Ampulla of Vater , Common Bile Duct Neoplasms/therapy , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adenocarcinoma/therapy , Ampulla of Vater/pathology , Ampulla of Vater/surgery , Carcinoma/pathology , Carcinoma/surgery , Carcinoma/therapy , Carcinoma, Pancreatic Ductal/pathology , Carcinoma, Pancreatic Ductal/surgery , Carcinoma, Pancreatic Ductal/therapy , Chemoradiotherapy, Adjuvant , Chemotherapy, Adjuvant , Common Bile Duct Neoplasms/pathology , Common Bile Duct Neoplasms/surgery , Duodenal Neoplasms/pathology , Duodenal Neoplasms/surgery , Duodenal Neoplasms/therapy , Humans , Pancreaticoduodenectomy , Radiotherapy, Adjuvant , Retrospective Studies , Treatment Outcome
6.
Hernia ; 23(6): 1123-1132, 2019 12.
Article in English | MEDLINE | ID: mdl-31325053

ABSTRACT

PURPOSE: Laparoscopic ventral and incisional hernia repair (LVIHR) has become a common procedure because of its feasibility and safety, but it is not free of complications. Acute and chronic post-operative pain and bleeding caused by traumatic fixation of the mesh are frequently prolonging the hospital stay. The aim of this study was to analyze the behavior of n-butyl-cyanoacrylate (GLUBRAN® 2) as only mesh fixation METHODS: Ten female pigs were involved in the study and were divided into two groups of five (A and B). Animals in each group underwent a laparoscopic procedure in which two meshes were placed intraperitoneally and fixed with the same synthetic glue only. Animals in group A were sacrificed after 3 weeks, and those in group B were sacrificed after 12 weeks. We studied the morphological, biomechanical, and histological characteristics of the intraperitoneal mesh-tissue interface RESULTS: No disruption, migration or folding was observed in any of the pigs. In group A, the mean tensile strength was 1.4 N/cm (± 0.2) while in group B, the mean tensile strength was 2.5 N/cm (± 0.8). Histological analyses, in areas where mesh was fixed using the glue, showed a chronic lymphocytic inflammatory reaction with a granulomatous component and a marked desmoplastic reaction made up of immature collagen and numerous fibroblasts acquiring myofibroblastic characteristics. In some areas corresponding to fixation, the desmoplastic reaction originated from mature lamellar bone tissue with osteocytes and osteoblasts. CONCLUSION: Laparoscopic mesh fixation with only the synthetic comonomer glue GLUBRAN® 2 is feasible, effective, and safe in intraperitoneal incisional/ventral hernia repair in this animal model.


Subject(s)
Cyanoacrylates/administration & dosage , Hernia, Ventral/surgery , Herniorrhaphy/methods , Incisional Hernia/surgery , Surgical Mesh , Animals , Female , Laparoscopy/instrumentation , Models, Animal , Peritoneum/surgery , Swine
8.
Clin. transl. oncol. (Print) ; 16(3): 243-256, mar. 2014.
Article in English | IBECS | ID: ibc-127731

ABSTRACT

The annual incidence of neuroendocrine tumours in the Caucasian population ranges from 2.5 to 5 new cases per 100,000 inhabitants. Gastroenteropancreatic neuroendocrine tumours is a family of neoplasms widely variable in terms of anatomical location, hormone composition, clinical syndromes they cause and in their biological behaviour. This high complexity and clinical heterogeneity, together with the known difficulty of predicting their behaviour from their pathological features, are reflected in the many classifications that have been developed over the years in this field. This article reviews the main tissue and clinical biomarkers and makes recommendations for their use in medical practice. This document represents a consensus reached jointly by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) (AU)


No disponible


Subject(s)
Humans , Intestinal Neoplasms/diagnosis , Neuroendocrine Tumors/diagnosis , Pancreatic Neoplasms/diagnosis , Stomach Neoplasms/diagnosis , Biomarkers, Tumor/analysis , Intestinal Neoplasms/metabolism , Neuroendocrine Tumors/metabolism , Pancreatic Neoplasms/metabolism , Stomach Neoplasms/metabolism
9.
Clin Transl Oncol ; 16(3): 243-56, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23749327

ABSTRACT

The annual incidence of neuroendocrine tumours in the Caucasian population ranges from 2.5 to 5 new cases per 100,000 inhabitants. Gastroenteropancreatic neuroendocrine tumours is a family of neoplasms widely variable in terms of anatomical location, hormone composition, clinical syndromes they cause and in their biological behaviour. This high complexity and clinical heterogeneity, together with the known difficulty of predicting their behaviour from their pathological features, are reflected in the many classifications that have been developed over the years in this field. This article reviews the main tissue and clinical biomarkers and makes recommendations for their use in medical practice. This document represents a consensus reached jointly by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).


Subject(s)
Biomarkers, Tumor/analysis , Intestinal Neoplasms/diagnosis , Neuroendocrine Tumors/diagnosis , Pancreatic Neoplasms/diagnosis , Stomach Neoplasms/diagnosis , Humans , Intestinal Neoplasms/metabolism , Neuroendocrine Tumors/metabolism , Pancreatic Neoplasms/metabolism , Stomach Neoplasms/metabolism
10.
Gene Ther ; 19(11): 1048-57, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22113313

ABSTRACT

The limitations of the current oncolytic adenoviruses for cancer therapy include insufficient potency and poor distribution of the virus throughout the tumor mass. To address these problems, we generated an oncolytic adenovirus expressing the hyperfusogenic form of the gibbon-ape leukemia virus (GALV) envelope glycoprotein under the control of the adenovirus major late promoter. The oncolytic properties of the new fusogenic adenovirus, ICOVIR16, were analyzed both in vitro and in vivo, and compared with that of its non-fusogenic counterpart, ICOVIR15. Our results indicate that GALV expression by ICOVIR16 induced extensive syncytia formation and enhanced tumor cell killing in a variety of tumor cell types. When injected intratumorally or intravenously into mice with large pre-established melanoma or pancreatic tumors, ICOVIR16 rapidly reduced tumor burden, and in some cases, resulted in complete eradication of the tumors. Importantly, GALV expression induced tumor cell fusion in vivo and enhanced the spreading of the virus throughout the tumor. Taken together, these results indicate that GALV expression can improve the antitumoral potency of an oncolytic adenovirus and suggest that ICOVIR16 is a promising candidate for clinical evaluation in patients with cancer.


Subject(s)
Adenoviridae/genetics , Genetic Vectors , Giant Cells , Leukemia Virus, Gibbon Ape/genetics , Oncolytic Viruses , Adenoviridae/metabolism , Animals , Cell Line, Tumor , Cricetinae , Female , Gene Expression Regulation, Viral , Gene Order , Genetic Therapy , Genetic Vectors/administration & dosage , Genetic Vectors/adverse effects , Genetic Vectors/metabolism , Giant Cells/virology , Humans , Injections , Male , Mice , Neoplasms/genetics , Neoplasms/pathology , Neoplasms/therapy , Tumor Burden , Xenograft Model Antitumor Assays
12.
Proc Natl Acad Sci U S A ; 104(1): 276-81, 2007 Jan 02.
Article in English | MEDLINE | ID: mdl-17190815

ABSTRACT

Nuclear functions for IkappaB kinase (IKK), including phosphorylation of histone H3 and nuclear corepressors, have been recently described. Here, we show that IKK is activated in colorectal tumors concomitant with the presence of phosphorylated SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor that is aberrantly localized in the cytoplasm. In these tumors, IKKalpha associates to the chromatin of specific Notch targets, leading to the release of SMRT. Abrogation of IKK activity by BAY11-7082 or by expressing dominant negative IKKalpha restores the association of SMRT with Notch target genes, resulting in specific gene repression. Finally, BAY11-7082 significantly reduces tumor size in colorectal cancer xenografts (CRC-Xs) implanted in nude mice.


Subject(s)
Cell Nucleus/enzymology , Colorectal Neoplasms/genetics , Gene Expression Regulation, Neoplastic , I-kappa B Kinase/physiology , Receptors, Notch/physiology , Animals , Cell Line , Enzyme Activation , Humans , Male , Mice , NF-kappa B/physiology , Nitriles/pharmacology , Phosphorylation , Repressor Proteins/physiology , Sulfones/pharmacology
17.
J Hepatol ; 26(4): 839-44, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9126797

ABSTRACT

BACKGROUND/AIMS: Inoculation of ascitic fluid into conventional blood culture bottles is more sensitive than conventional culture in the diagnosis of spontaneous bacterial peritonitis. BacT/ALERT is an automated colorimetric microbial detection system that has been shown to be faster than conventional blood culture bottles in the diagnosis of bacteremia. The aim of the study was to compare the BacT/ALERT system with the conventional culture and the conventional blood culture bottles method in the diagnosis of spontaneous bacterial peritonitis. METHODS: All the ascitic fluid samples from patients with cirrhosis hospitalized in our Department between September 1992 and May 1994 (n=1032) were prospectively evaluated. In all cases, an aliquot of ascitic fluid was sent for Gram's stain and conventional culture, and 20 ml were inoculated at the bedside into blood culture bottles: 10 ml into conventional blood culture bottles and 10 ml into BacT/ALERT. RESULTS: Thirty ascitic fluid infections (23 spontaneous bacterial peritonitis and 7 neutrocytic ascites) and 20 bacterascites were diagnosed. Conventional culture was positive in 10/30 ascitic fluid infections (33.3%), conventional blood culture bottles in 22/30 (73.3%) (p<0.01 compared to conventional culture) and BacT/ALERT in 20/30 (66.6%) (p<0.05 compared to conventional culture, pNS compared to conventional blood culture bottles). The time elapsed for culture positivity was 43.4+/-34.2 h for conventional blood culture bottles and 13.3+/-9.2 h for BacT/ALERT (p<0.001). Thirteen of the 23 cases of spontaneous bacterial peritonitis (56.5%) were detected within the first 12 h with BacT/ALERT, as compared to only three (13%) with conventional blood culture bottles (p<0.03). CONCLUSION: The automated system BacT/ALERT provides an earlier microbiologic diagnosis of spontaneous bacterial peritonitis than conventional blood culture bottles with similar sensitivity.


Subject(s)
Bacterial Infections/diagnosis , Colorimetry , Microbiological Techniques , Peritonitis/microbiology , Anti-Bacterial Agents/therapeutic use , Ascitic Fluid/microbiology , Automation , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Drug Resistance, Microbial , Humans , Liver Cirrhosis/microbiology , Prospective Studies , Sensitivity and Specificity , Time Factors
18.
Hepatology ; 25(3): 532-6, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9049193

ABSTRACT

Cirrhotic patients with ascites and low ascitic fluid total protein and/or high serum bilirubin levels are at high risk to develop the first episode of spontaneous bacterial peritonitis during long-term follow-up. The aim of the present study was to determine the efficacy of continuous long-term selective intestinal decontamination with norfloxacin in the prevention of this complication. One hundred nine cirrhotic patients with ascites and ascitic fluid total protein levels of < or = 1 g/dL or serum bilirubin levels of > 2.5 mg/dL without previous spontaneous bacterial peritonitis were prospectively randomized into two groups: group 1 (n = 56) received norfloxacin, 400 mg daily administered orally, and group 2 (n = 53) was the long-term control group, receiving norfloxacin only during hospitalization. During a mean follow-up of 43 +/- 3 weeks, there was one spontaneous bacterial peritonitis (1.8%) in group 1 and 9 (16.9%) in group 2 (P < .01). The incidence of community-acquired spontaneous bacterial peritonitis was lower in group 1 (1.8% vs. 13.2%, P < .05), whereas the incidence of nosocomial spontaneous bacterial peritonitis (0% vs. 3.7%) and the incidence of extraperitoneal infections (25% vs. 24.5%) were similar in both groups (P = NS). The actuarial probability of survival at 18 months was 75% in group 1 and 62% in group 2 (P = NS). Resistance to norfloxacin was observed in 9 of 10 (90%) Escherichia coli isolated in infections from group 1 and in 4 of 11 (36.3%) from group 2 (P < .05). The overall incidence of infections caused by norfloxacin-resistant bacteria was higher in group 1 (19.6% vs. 15%), but it did not reach statistical significance. Continuous long-term selective intestinal decontamination with norfloxacin is effective in preventing the first spontaneous bacterial peritonitis in cirrhotic patients at high risk. However, the emergence of infections caused by norfloxacin-resistant bacteria must be weighed carefully against the benefits of continuous long-term prophylaxis.


Subject(s)
Anti-Infective Agents/therapeutic use , Bacterial Infections/prevention & control , Liver Cirrhosis/complications , Norfloxacin/therapeutic use , Peritonitis/prevention & control , Ascites/complications , Bacterial Infections/epidemiology , Bacterial Infections/microbiology , Drug Administration Schedule , Drug Resistance, Microbial , Female , Follow-Up Studies , Hospitalization , Humans , Incidence , Male , Middle Aged , Peritonitis/epidemiology , Peritonitis/microbiology
19.
N Engl J Med ; 334(25): 1624-9, 1996 Jun 20.
Article in English | MEDLINE | ID: mdl-8628357

ABSTRACT

BACKGROUND: Patients who have bleeding from esophageal varices are at high risk for rebleeding and death. We compared the efficacy and safety of endoscopic sclerotherapy with the efficacy and safety of nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. METHODS: Eighty-six hospitalized patients with cirrhosis and bleeding from esophageal varices diagnosed by endoscopy were randomly assigned to treatment with repeated sclerotherapy (43 patients) or nadolol plus isosorbide-5-mononitrate (43 patients). The primary outcomes were rebleeding, death, and complications. The hepatic venous pressure gradient was measured at base line and after three months. RESULTS: Base-line data were similar in the two groups, and the median follow-up was 18 months in both. Eleven patients in the medication group and 23 in the sclerotherapy group had rebleeding. The actuarial probability of remaining free of rebleeding was higher in the medication group for all episodes related to portal hypertension (P = 0.001) and variceal rebleeding (P = 0.002). Four patients in the medication group and nine in the sclerotherapy group died (P = 0.07 for the difference in the actuarial probability of survival). Seven patients in the medication group and 16 in the sclerotherapy group had treatment-related complications (P = 0.03). Thirty-one patients in the medication group underwent two hemodynamic studies; 1 of the 13 patients with more than a 20 percent decrease in the hepatic venous pressure gradient had rebleeding, as compared with 8 of the 18 with smaller decreases in the pressure gradient (P = 0.04) for the actuarial probability of rebleeding at two years). CONCLUSIONS: As compared with sclerotherapy, nadolol plus isosorbide mononitrate significantly decreased the risk of rebleeding from esophageal varices.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Esophageal and Gastric Varices/therapy , Gastrointestinal Hemorrhage/prevention & control , Isosorbide Dinitrate/analogs & derivatives , Nadolol/therapeutic use , Sclerotherapy , Vasodilator Agents/therapeutic use , Actuarial Analysis , Adrenergic beta-Antagonists/adverse effects , Drug Therapy, Combination , Esophageal and Gastric Varices/drug therapy , Esophageal and Gastric Varices/mortality , Female , Humans , Isosorbide Dinitrate/therapeutic use , Male , Middle Aged , Nadolol/adverse effects , Recurrence , Sclerotherapy/adverse effects , Survival Analysis , Treatment Outcome
20.
Eur J Nucl Med ; 22(10): 1123-8, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8542895

ABSTRACT

The aim of this study was to assess the gastric emptying rate of two antacids using an scintigraphic technique and simultaneous monitoring of gastric pH in 16 healthy male volunteers. Ten ml of Talcid (hydrotalcite 1 g) and Maalox (Mg-Al-hydroxide), with a similar neutralization capacity, were labelled with technetium-99m using a pyrophosphate bridge. Labelled antacids were given on separate days (within 2 weeks), 1 h after a standard meal. Intragastric pH was measured for at least 4 h, using ambulatory pH-metry with a dual-crystant antimony catheter. Continuous monitoring was started 1 h prior to the meal (baseline) and lasted 3 h (post-prandial, post-antacid and final periods). The antacid capacity of labelled and unlabelled antacids was similar. The mean percentages of antacids retained in the stomach fitted a linear model. The mean half-emptying time of Talcid was 63.9 +/- 27.9 min, while that of Maalox was 57.3 +/- 23.9 min (P = NS). The recordings of gastric pH (mean values of pH for each period) showed a similar profile for both antacids. The mean pH (Maalox vs Talcid) was 1.69 vs 2.07 in the baseline period, 1.95 vs 1.93 in the post-prandial period, 1.79 vs 1.15 in the post-antacid period (P = NS) and 0.4 vs 0.52 in the final period (P < 0.05 vs prior periods). In conclusion, the gastric emptying of Talcid and Maalox was similar and pH profiles were parallel and remained unchanged for the two antacids within the first hour of intake. A significant decrease in pH was observed 1 h after intake of the antacids, suggesting a possible rebound effect.


Subject(s)
Aluminum Hydroxide , Antacids , Gastric Emptying , Magnesium Hydroxide , Adult , Aluminum Hydroxide/pharmacokinetics , Aluminum Hydroxide/pharmacology , Antacids/pharmacokinetics , Antacids/pharmacology , Cross-Over Studies , Double-Blind Method , Drug Combinations , Gastric Acidity Determination , Humans , Hydrogen-Ion Concentration , Magnesium Hydroxide/pharmacokinetics , Magnesium Hydroxide/pharmacology , Male , Technetium Tc 99m Pyrophosphate
SELECTION OF CITATIONS
SEARCH DETAIL
...